| 6th Jan 2022 5:30 pm |
RNS |
Amryt Pharma |
| 6th Jan 2022 7:00 am |
GNW |
Key Dates for AIM Delisting |
| 4th Jan 2022 12:00 pm |
GNW |
The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients |
| 4th Jan 2022 7:00 am |
GNW |
Total Voting Rights |
| 1st Dec 2021 7:00 am |
GNW |
Total Voting Rights |
| 30th Nov 2021 7:00 am |
GNW |
Director/PDMR Shareholding |
| 23rd Nov 2021 12:00 pm |
GNW |
Amryt Provides Update on Regulatory Review Process for Oleogel-S10 |
| 22nd Nov 2021 7:00 am |
GNW |
Amryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM |
| 3rd Nov 2021 11:00 am |
GNW |
Amryt Reports Strong Q3 2021 Results |
| 1st Nov 2021 1:00 pm |
GNW |
Total Voting Rights |
| 1st Nov 2021 7:00 am |
RNS |
Amryt Supports Acromegaly Awareness Day |
| 22nd Oct 2021 7:00 am |
RNS |
Amryt Supports Global EB Awareness Week 2021 |
| 20th Oct 2021 12:00 pm |
GNW |
Amryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3 |
| 19th Oct 2021 12:00 pm |
GNW |
Amryt Announces New Patents for Oleogel-S10 and Mycapssa® |
| 23rd Sep 2021 12:00 pm |
RNS |
Amryt Supports Global FH Awareness Day |
| 13th Sep 2021 12:00 pm |
GNW |
Amryt Raises Full Year 2021 Revenue Guidance to $220M - $225M |
| 1st Sep 2021 7:00 am |
GNW |
Total Voting Rights |
| 19th Aug 2021 7:00 am |
GNW |
Amryt Issues Ordinary Shares and Total Voting Rights |
| 13th Aug 2021 1:23 pm |
RNS |
Holding(s) in Company - Replacement |
| 11th Aug 2021 11:30 am |
RNS |
Holdings in Company |
| 11th Aug 2021 10:36 am |
RNS |
Holding(s) in Company |
| 10th Aug 2021 2:20 pm |
GNW |
Director/PDMR Shareholding |
| 10th Aug 2021 9:53 am |
RNS |
Holding(s) in Company |
| 9th Aug 2021 12:00 pm |
GNW |
Amryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT |
| 6th Aug 2021 12:00 pm |
GNW |
Amryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance |
| 5th Aug 2021 3:50 pm |
GNW |
Amryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights |
| 28th Jul 2021 3:00 pm |
GNW |
Result of General Meetings |
| 12th Jul 2021 12:00 pm |
GNW |
Amryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6 |
| 28th Jun 2021 12:00 pm |
GNW |
Publication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings |
| 15th Jun 2021 11:45 am |
GNW |
Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc. |
| 7th Jun 2021 12:00 pm |
GNW |
FDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting |
| 3rd Jun 2021 7:00 am |
GNW |
FDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa |
| 2nd Jun 2021 1:30 pm |
GNW |
Amryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa |
| 5th May 2021 4:41 pm |
RNS |
Second Price Monitoring Extn |
| 5th May 2021 4:35 pm |
RNS |
Price Monitoring Extension |
| 5th May 2021 12:05 pm |
GNW |
Amryt Reports Record Q1 2021 Financial and Operating Results |
| 5th May 2021 12:00 pm |
GNW |
Amryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases |
| 15th Apr 2021 12:00 pm |
GNW |
Amryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5 |
| 6th Apr 2021 7:00 am |
GNW |
Amryt Announces the Appointment of Sheila Frame as President Americas |
| 31st Mar 2021 11:00 am |
RNS |
Amryt Supports World Lipodystrophy Day |
